{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for obeticholic root_relationships_comments in Relationship Comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT02964403: Phase 4 Interventional Unknown status Pancreatitis, Acute
(2016)
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2019)
Source:
NDA212194
(2019)
Source URL:
First approved in 2019
Source:
NDA212194
Source URL:
Class:
NUCLEIC ACID
Status:
US Approved Rx
(1996)
Source:
NDA020248
(1996)
Source URL:
First approved in 1975
Source:
INTRALIPID 10% by FRESENIUS
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved OTC
Source:
21 CFR 357.210(a) cholecystokinetic corn oil, aqueous emulsion
Source URL:
First approved in 1978
Source:
NDA018081
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:labafenogene marselecobac [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03918629: Phase 3 Interventional Completed Clostridium Difficile Associated Disease
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Allergenic Extract
(1972)
Source:
BLA102192
(1972)
Source URL:
First approved in 1972
Source:
BLA102192
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Allergenic Extract
(1972)
Source:
BLA102192
(1972)
Source URL:
First marketed in 1921
Source:
Oil of Theobroma U.S.P.
Source URL:
Class:
STRUCTURALLY DIVERSE
